Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling

被引:96
作者
de Zwart, L. [1 ]
Snoeys, J. [1 ]
De Jong, J. [2 ]
Sukbuntherng, J. [3 ]
Mannaert, E. [1 ]
Monshouwer, M. [1 ]
机构
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Res & Dev, San Diego, CA USA
[3] Pharmacyclics Inc, Sunnyvale, CA USA
关键词
DRUG-DRUG INTERACTIONS; IN-VITRO DATA; HEALTHY-VOLUNTEERS; POPULATION PHARMACOKINETICS; ALPHA-1-ACID GLYCOPROTEIN; MIDAZOLAM CLEARANCE; INHIBITION; PREDICTION; KETOCONAZOLE; FLUVOXAMINE;
D O I
10.1002/cpt.419
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Based on ibrutinib pharmacokinetics and potential sensitivity towards CYP3A4-mediated drug-drug interactions (DDIs), a physiologically based pharmacokinetic approach was developed to mechanistically describe DDI with various CYP3A4 perpetrators in healthy men under fasting conditions. These models were verified using clinical data for ketoconazole (strong CYP3A4 inhibitor) and used to prospectively predict and confirm the inducing effect of rifampin (strong CYP3A4 inducer); DDIs with mild (fluvoxamine, azithromycin) and moderate inhibitors (diltiazem, voriconazole, clarithromycin, itraconazole, erythromycin), and moderate (efavirenz) and strong CYP3A4 inducers (carbamazepine), were also predicted. Ketoconazole increased ibrutinib area under the curve (AUC) by 24-fold, while rifampin decreased ibrutinib AUC by 10-fold; coadministration of ibrutinib with strong inhibitors or inducers should be avoided. The ibrutinib dose should be reduced to 140 mg (quarter of maximal prescribed dose) when coadministered with moderate CYP3A4 inhibitors so that exposures remain within observed ranges at therapeutic doses. Thus, dose recommendations for CYP3A4 perpetrator use during ibrutinib treatment were developed and approved for labeling.
引用
收藏
页码:548 / 557
页数:10
相关论文
共 50 条
[1]   Deciding on Success Criteria for Predictability of Pharmacokinetic Parameters from In Vitro Studies: An Analysis Based on In Vivo Observations [J].
Abduljalil, Khaled ;
Cain, Theresa ;
Humphries, Helen ;
Rostami-Hodjegan, Amin .
DRUG METABOLISM AND DISPOSITION, 2014, 42 (09) :1478-1484
[2]  
Aguirre C, 1996, RES COMMUN MOL PATH, V92, P53
[3]  
[Anonymous], 2015, SAFETY EFFICACY PCI
[4]   Population pharmacokinetics of APOMINE™:: A meta-analysis in cancer patients and healthy males [J].
Bonate, PL ;
Floret, S ;
Bentzen, C .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (02) :142-155
[5]   Use of intrinsic clearance for prediction of human hepatic clearance [J].
Chao, Piyun ;
Uss, Annette S. ;
Cheng, K. C. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2010, 6 (02) :189-198
[6]   A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer [J].
Cheeti, Sravanthi ;
Budha, Nageshwar R. ;
Rajan, Sharmila ;
Dresser, Mark J. ;
Jin, Jin Y. .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2013, 34 (03) :141-154
[7]   Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development [J].
Chiba, Masato ;
Ishii, Yasuyuki ;
Sugiyama, Yuichi .
AAPS JOURNAL, 2009, 11 (02) :262-276
[8]   Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole [J].
Chien, Jenny Y. ;
Lucksiri, Aroonrut ;
Ernest, Charles S., II ;
Gorski, J. Christopher ;
Wrighton, Steven A. ;
Hall, Stephen D. .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (07) :1208-1219
[9]   Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use [J].
Damle, Bharat ;
Varma, Manthena V. ;
Wood, Nolan .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (11) :5172-5177
[10]   Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants [J].
de Jong, Jan ;
Skee, Donna ;
Murphy, Joe ;
Sukbuntherng, Juthamas ;
Hellemans, Peter ;
Smit, Johan ;
de Vries, Ronald ;
Jiao, Juhui James ;
Snoeys, Jan ;
Mannaert, Erik .
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2015, 3 (04)